Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
In a small, carefully controlled study, seven people with major depression each received a single low-dose ketamine infusion on one day and a saline infusion on another day, without anyone knowing which was which. People who got ketamine showed clear improvement in their depressive symptoms within three days, while those…
In a small, controlled study of 18 people with treatment-resistant major depression, a single intravenous dose of the NMDA receptor antagonist ketamine (0.5 mg/kg) produced rapid drops in depression scores. Improvement began within about 2 hours and remained statistically significant compared with placebo for up to 1 week. The study…
Researchers tested a nasal spray form of esketamine together with a newly started oral antidepressant in adults whose depression had not improved after trying at least two antidepressants. Over four weeks, people who got esketamine plus a new antidepressant had faster and larger drops in depression symptoms than those who…
This phase 3, double-blind trial tested whether continuing esketamine nasal spray plus an oral antidepressant could delay relapse in adults with treatment-resistant depression who had already improved after an initial esketamine course. Of 297 patients who entered the randomized phase, continuing esketamine reduced relapse compared with switching to placebo nasal…
Repeated ketamine infusions have cumulative and sustained antidepressant effects. Reductions in depressive symptoms were maintained among responders through once-weekly infusions. These findings provide novel data on efficacious administration strategies for ketamine in patients with treatment-resistant depression. Future studies should further expand on optimizing administration to better translate the use of…
This multi-site, randomized, double-blind phase 3 trial tested MDMA-assisted therapy (MDMA-AT) versus placebo with the same therapy in 104 people with moderate to severe PTSD. Blinded assessors found larger average reductions in PTSD symptoms and in functional impairment for the MDMA-AT group than for the placebo group. The MDMA group…
This study demonstrated that treatment with three infusions of ketamine was well tolerated in patients with alcohol use disorder and was associated with more days of abstinence from alcohol at 6-month follow-up. The findings suggest a possible beneficial effect of adding psychological therapy alongside ketamine treatment.
This randomized, double-blind trial tested whether six low-dose ketamine infusions over 12 days worked better than a single ketamine infusion for people with treatment-resistant depression. At 24 hours after the last infusion, there was no significant difference in clinician-rated depression scores between the group that received six ketamine infusions and…
This is a theoretical review that looks at depression from both Western medicine and traditional Chinese medicine (TCM). It says depression is an emotion regulation disorder and is common worldwide. The paper reviews ideas from both systems and suggests possible brain and body pathways that could link TCM concepts of…
This review looked at published clinical trials of psilocybin for depression. It found 11 trials (six open‑label and five double‑blind randomized trials) that report rapid antidepressant and anti‑anxiety effects in some patients. The paper describes how psilocybin acts on serotonin 5‑HT2A receptors, may boost brain plasticity, and may lower brain…
(Reprinted with permission from The American Journal of Psychiatry 2019; 176:401-409).
